Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2018 February;153(1) > Giornale Italiano di Dermatologia e Venereologia 2018 February;153(1):102-6

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Giornale Italiano di Dermatologia e Venereologia 2018 February;153(1):102-6

DOI: 10.23736/S0392-0488.17.05781-9

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

The use of minoxidil in the treatment of male and female androgenetic alopecia: a story of more than 30 years

Mauro BARBARESCHI

Unit of Dermatology, Department of Medical and Transplantation Physiopathology, Ca’ Granda Ospedale Maggiore Policlinico Foundation, University of Milan, Milan, Italy


PDF


Even if minoxidil has been known for over 30 years as “hair growth stimulator” the precise mechanism of its action is not completely elucitated. Minoxidil shortens telogen, accelerates telogen-exogen phase and causes the premature entry of resting hair follicles into anagen phase. Moreover, minoxidil increases hair follicle size. A large part of hair treatment scientific literature confirms the efficacy of topically applied minoxidil in humans. In particular, patients treated with minoxidil showed a significant increase in “non vellus” hair count starting from baseline. Preparation of minoxidil requires molecule stability and solubility. Today are available on the market minoxidil-based formulations having low-concentration of propylene glycol to obtain preparations with a better cosmetical acceptance and dermatological safety. The body of evidences indicates that minoxidil still represent a milestone in the treatment of androgenetic alopecia and that its story is going on.


KEY WORDS: Alopecia - Minoxidil - Treatment outcome - Propylene glycol

inizio pagina